Israel-based RedHill Biopharma has partnered with the US National Institute of Allergy and Infectious Diseases (NIAID) to study its RHB-107 (upamostat, WX-671) drug candidate in non-clinical tests for the treatment of Covid-19.
RHB-107 is a serine protease inhibitor active against various human trypsins and other related serine proteases. It is an experimental drug evaluated in more than 300 people across ten clinical studies, including Phase I and II trials for cancer treatment.
Data from these studies validated the drug candidate’s safety and tolerability in humans said the company. The company expects that serine proteases inhibition, including trypsins, to block viral attachment and replication while mitigating lung damage from